- $73.26bn
- $68.43bn
- $7.26bn
- 96
- 14
- 89
- 73
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,627 | 4,318 | 5,139 | 6,216 | 7,259 |
Cost of Revenue | |||||
Gross Profit | 2,562 | 3,120 | 3,711 | 4,501 | 5,488 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 4,129 | 4,567 | 5,255 | 6,438 | 7,076 |
Operating Profit | -502 | -249 | -116 | -222 | 183 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -482 | -275 | 16.2 | -260 | 356 |
Provision for Income Taxes | |||||
Net Income After Taxes | -481 | -282 | 29.4 | -367 | 1,381 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -481 | -282 | 29.4 | -367 | 1,381 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -481 | -282 | 36 | -367 | 1,664 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.12 | -1.19 | 0.142 | -1.44 | 6.27 |